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ABSTRACT
Background Electronic systems that facilitate prescribing, administration and 
dispensing of medicines (ePrescribing systems) are at the heart of international 
efforts to improve the safety, quality and efficiency of medicine management. Con-
sidering the initial costs of procuring and maintaining ePrescribing systems, there is 
a need to better understand how to accelerate and maximise the financial benefits 
associated with these systems.
Objectives We sought to investigate how different sectors are approaching the 
realisation of returns on investment from ePrescribing systems in U.K. hospitals 
and what lessons can be learned for future developments and implementation 
strategies within healthcare settings.
Methods We conducted international, multi-disciplinary, round-table discussions 
with 21 participants from different backgrounds including policy makers, healthcare 
organisations, academic researchers, vendors and patient representatives. The 
discussions were audio-recorded, transcribed and then thematically analysed with 
the qualitative analysis software NVivo10.
Results There was an over-riding concern that realising financial returns from 
ePrescribing systems was challenging. The underlying reasons included substan-
tial fixed costs of care provision, the difficulties in radically changing the medicines 
management process and the lack of capacity within NHS hospitals to analyse 
and exploit the digital data being generated. Any future data strategy should take 
into account the need to collect and analyse local and national data (i.e. within and 
across hospitals), setting comparators to measure progress (i.e. baseline measure-
ments) and clear standards guiding data management so that data are comparable 
across settings.
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Conclusions A more coherent national approach to realising financial ben-
efits from ePrescribing systems is needed as implementations progress and the 
range of tools to collect information will lead to exponential data growth. The 
move towards more sophisticated closed-loop systems that integrate prescrib-
ing, administration and dispensing, as well as increasingly empowered patients 
accessing their data through portals and portable devices, will accelerate these 
developments. Meaningful analysis of data will be the key to realise benefits 
associated with systems.
Keywords: data analytics, ePrescribing, returns on investment 
INTRODUCTION
There is considerable international interest in relation to 
health information technologies (HITs) in order to improve 
the quality, safety and efficiency of care.1–4 Evidence of 
effectiveness of these systems, however, is often equivo-
cal, particularly in relation to their impact on patient out-
comes and financial returns.5 Underlying reasons may 
include the infrastructural characteristics of HITs, and the 
fact that their diffuse effects are often hard to trace and pre-
dict in advance.6,7 Establishing a causal link between HITs 
and patient outcomes is extremely difficult, and changes in 
business processes brought about by such transformative 
implementations can mean that baseline comparisons are 
close to impossible. In addition, benefits may not appear 
as a direct consequence of implementation. They may 
result from later benefit realisation efforts that pursue 
health pathway improvements from the information col-
lected or the scope for further extension of systems. As 
a result, there may be a problem in attributing improve-
ments to the investments in the core infrastructure. Other 
underlying factors may relate to the difficulty measuring 
non-financial benefits. Returns on investments (RoIs) are 
typically calculated by weighing up financial investments 
against resulting benefits, but these benefits are not nec-
essarily financially measurable (e.g. patient experience) 
and not all risks may adequately be taken into account 
(e.g. adverse effects on work practices).
Electronic systems that help hospitals manage prescrib-
ing, administration and dispensing of medication (or ePre-
scribing systems) represent a relatively direct link between 
the technology and prescribing/clinical outcomes. They are 
therefore a good starting point to begin exploring benefits 
and costs.5 They are, however, expensive, both in terms of 
startup and maintenance.8 Consequently, as a result of the 
considerable cost investment required and at a time when 
health systems are financially struggling, there is a substan-
tial interest in how to maximise financial RoIs. For example, 
the predicted £2.5 billion deficit in the U.K. National Health 
Service (NHS) is a problem that needs to be addressed and 
central to this is the financial performance of hospitals.9 
However, hospitals and policy makers are by no means 
alone in wanting to demonstrate financial benefits. Industry 
has long-standing interest in this area and has been very 
successful at scaling and measuring system optimisation 
approaches (i.e. refining systems and ensuring that they 
realise anticipated benefits) in sectors including media and 
communications, banking and retail. For example, the bank-
ing industry has made significant leaps in developing and 
implementing mobile banking services, which are estimated 
to have resulted in a 15.7 % RoI.10 
Central to these efforts are increasingly technology 
investments in ‘Big Data’ that allow organisations to anal-
yse large volumes of information and use this information 
for efficiency and quality improvements.11 Data analytics 
(i.e. reusing data for managerial purposes) therefore also 
represents a major opportunity for realising financial ben-
efits of HITs, a development that is supported by some pio-
neering health systems that draw on secondary uses of 
data to realise financial returns.12–15
Given the paucity of international evidence on 
this subject,5,16 we convened an international expert 
 multi-disciplinary group to explore how different sectors 
are approaching the realisation of RoIs from ePrescribing 
systems in U.K. hospitals and what lessons can be learned 
for future developments and implementation strategies 
within healthcare settings.
MeThODS
ethics and consent
The work was reviewed by the Nursing Studies Ethics 
Review Panel at The University of Edinburgh (UK) and 
received approval in November 2014. Participants gave 
written informed consent to participate in the discussions. 
Names and places were anonymised when reporting data 
in order to protect the anonymity of participants.
Design
We conducted multi-disciplinary round-table discussions, 
which were organised as a series of focus groups with 
two designated facilitators (JC and CS) with clinical back-
grounds.17 As we deliberately tried to explore cross-sector 
experiences and stimulate the exchange of ideas, this inter-
active format of qualitative data collection was deemed most 
appropriate. 
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Sampling and recruitment of participants
Our sampling strategy was purposeful.18 As part of related 
work evaluating the introduction of ePrescribing systems 
in English hospitals,3 we have been populating a list of 
 national and international leading figures with experience of, 
or  interest in, implementing/using ePrescribing systems. In 
line with our aims, we initially divided potential participants 
into sectors including representatives from policy (with the 
aim to get insights into current and future policies), health-
care  organisations (aiming to draw on their experiences and 
exploring the practical feasibility of discussed options), aca-
demic  researchers (drawing on theoretical insights and future 
work), patients (investigating potential impacts on perceived 
care and related concerns), and industry (seeking to learn 
from experiences in other settings). We approached prescrib-
ing software companies that either had a significant market 
share in the U.K. already or were beginning to establish them-
selves in the U.K. market. The leading organisations were 
then listed and invitations to the most senior figures were sent 
out initially (targeting chief executives in the first instance). In 
some cases (no = 3), our email was then passed on to the 
organisational representative that was deemed most appro-
priate. We invited 31 individuals, of whom six did not respond 
to our invitations. A further four agreed to participate, but did 
not attend on the day, due to extenuating circumstances. 
Setting
The series of round-table discussions took place at The 
University of Edinburgh, U.K. in February 2015. The room 
was set up in boardroom style. One international participant 
dialled in via Skype.
Data collection and handling 
The event was arranged around four topic areas, which were 
divided into two parts (see Box 1): 1) maximising benefits and 
RoIs and 2) data analytics. The topic guide was developed joint-
ly by the authors and was sent out to participants for comments 
before the event, which resulted in minor modifications (mainly 
relating to more detailed areas of discussion).
Box 1 Key topics discussed 
PART 1:    Maximising benefits and RoIs
Topic I:      What are the potential RoIs from ePrescribing 
and related systems? 
Topic II:       How can RoIs identified in Topic 1 be accelerated/
maximised?
PART 2:    Data analytics 
Topic III:  Current analytics infrastructure, expertise and 
approaches 
Topic IV:  Looking ahead: future developments in soft-
ware, data linkage and analytics
One facilitator (CS) led the first part of the discussions, whilst 
the other (JC) led the second part of the discussions. Each 
session began with a brief introduction of the topic followed by 
subsequent dialog by participants. By prompting participants 
who had not spoken at the end of each topic, facilitators helped 
to ensure that a range of viewpoints was heard. A coffee break 
between the two sessions helped participants to more informal-
ly exchange experiences and facilitated networking.
We audio-recorded the event and transcribed the record-
ings verbatim. In addition, a researcher (KC) took field notes 
on the speakers and the observed dynamics to aid interpreta-
tion of results. Audio recordings were transcribed by a profes-
sional transcriber, checked for accuracy by a researcher (KC) 
and uploaded into NVivo10 software for analysis.19 
Data analysis
Verbal data were initially coded along the four topic areas by KC 
(the deductive element).20 As special attention was paid to cap-
turing emerging themes (the inductive element),20 these were 
created as the researcher examined the transcripts in more 
detail to reflect recurring issues in the discussions. Attention was 
also paid to capturing points relating to different perspectives 
on the same phenomenon (as a variety of backgrounds rep-
resented were an important design feature). Theoretically, we 
drew on the work surrounding information infrastructures. This 
helped us to examine the technological dimension surround-
ing the uses and reuses of digitised health data.21 Information 
infrastructures are characterised by distributed linked technolo-
gies that support information sharing/analysis on large scales 
and between settings. They also tend to have a multiplicity of 
users and uses, which extend beyond those anticipated in initial 
design. As a result, information infrastructures pose a very dif-
ferent set of technological challenges than more discrete tech-
nologies (e.g. in relation to ease of use, integration of systems).
Results of this initial analysis were fed back to the research 
team and subsequent discussions helped to refine themes 
and subthemes. This refined set of results was then fed back 
to attending participants for comments, which lead to minor 
modifications mainly in relation to the level of detail in sub-
themes.22
Results
Twenty-one participants took part in our discussions. 
These included participants representing a variety of 
sectors (see Box 2).
Box 2 Characteristics of participants
5 females and 16 males
4 NHS pharmacists
5  prescribing software company representatives  
(4 national and 1 international)
4 academics
2 policy representatives
2 industry representatives
1 NHS consultant
1 pharmaceutical company representative
1 innovation centre representative
1 patient 
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The following key themes emerged from these discussions 
(Box 3):
 • Inadequate capability to collect and analyse existing 
financial data 
 • Achieving improvements in safety, quality of care and 
organisational efficiency 
 • Developing a national data strategy to allow analysis 
of generalised data
 • Looking ahead: capturing and real-time analysis of 
data to predict care pathways.
These will be examined in detail below.
Box 3 Summary of themes
Inadequate capability to collect and analyse existing 
financial data 
-  Direct financial benefits and efficiency savings are hard 
to identify and measure
- Anonymisation of data and accessibility
-  Insufficient appropriate infrastructure and resources to 
collect and meaningfully analyse data
Achieving improvements in safety, quality of care and 
organisational efficiency 
-  Using ePrescribing systems to improve safety, quality 
and efficiency
-  More efficient capturing and analysis of data by ‘doing 
simple things well’
-  Engaging users and organisations through data 
availability and easy-to-use tools
- Learning lessons
Developing a national data strategy to allow analysis 
of generalised data
- The difference between specific and generalised data
-  A national data strategy with data standards and access 
arrangements
-  A gold standard against which progress can be 
measured
Looking ahead: capturing and real-time analysis of 
data to predict care pathways
- Exponential growth in data
- The continuing rise of portable technologies 
-  Predictive data analytics applied to care pathways 
including medicines management
- Robust commercial and research partnerships
Inadequate capability to collect and analyse 
existing financial data 
Participants agreed that direct financial benefits and effi-
ciency savings resulting from the introduction of ePrescribing 
systems were not only hard to identify but also hard to quan-
tify. The underlying difficulty was perceived to be the fact that 
many observed system benefits were qualitative in nature, 
such as improvements in value to patients, which resulted 
in difficulties measuring quantifiable benefits and calculating 
financial returns. A related issue was that existing financial 
benefits were not cash releasing, and hence hard to trace. 
‘…you struggle with what are the benefits and sometimes, 
you can see the clinical benefits but…the direct financial 
benefits are actually very interesting… I’m sure there are 
endless financial benefits indirectly.’ Participant 12, NHS 
Pharmacist
Another factor inhibiting meaningful analysis of quantita-
tive evidence and calculation of efficiency savings was an 
inadequate infrastructure and associated resources for data 
analytics within the NHS. This not only included financial 
resources to support system procurement and implementa-
tion, but also a lack of data analytics and benefits realisa-
tion expertise within hospitals. For example, an inadequate 
understanding of current processes and attached costs was 
a frequently mentioned barrier to estimating potential RoIs.
‘…we pay people fixed amounts of money for each pro-
cedure they do, so it’s kind of important that we under-
stand whether or not that has any relationship with cost, 
but about 50% of the hospitals are basically clueless, I 
mean literally clueless as to what the return costs are.’ 
Participant 7, Industry
Similarly, it was felt that managers within the NHS would 
put in capital investment for systems and then expect them 
to deliver, but participants from NHS hospitals that had imple-
mented these systems argued that in reality systems needed 
to be ‘nurtured’, in terms of constant refinement and relation-
ships with suppliers, to really deliver benefits. This aspect of 
longer-term support for system optimisation was often seen 
to be underestimated and underappreciated in the NHS. 
‘…the NHS tends to think of putting in an eHealth system 
as what I would call ‘Wash and Go’, you put them in and 
you walk away and you just don’t do that, you have to 
nurture them.’ Participant 1, NHS Pharmacist
Anonymisation of data and accessibility arrangements 
were also discussed as important challenges to tracing ben-
efits, as they may inhibit meaningful analysis of inter-organ-
isational data and prevent the NHS from exploiting existing 
datasets for maximum benefit. A more altruistic sharing of 
personal data amongst patients was viewed as an important 
facilitator and being able to trace data back to individual us-
ers (e.g. clinicians) and patients was seen as a fundamental 
pre-requisite to achieving maximum benefits. 
‘The biggest challenge that I see in the NHS is owner-
ship of data, if people could actually find who owns the 
data then actually the [technological] tools are there, 
you know infinite cloud computing capabilities, machine 
learning to take insight from your data and give predic-
tive outputs...’ Participant 3,  Researcher
Achieving improvements in safety, quality of 
care and organisational efficiency
Despite the issues outlined above, participants agreed 
that ePrescrbing systems offered a significant potential for 
decreasing the costs of care provision. Representatives from 
some pioneering U.K. institutions present outlined several 
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categories of benefits, although these were proxies for finan-
cial benefits in discreet areas.
These included: 
 • Clinical benefits: e.g. reduced omitted doses, more 
medicines given on time, more efficient prescribing 
through clinical decision support and computerised 
order entry systems (e.g. formulary switching), 
reduced prescribing errors, improved legibility, linking 
medications to clinical pathways, and antimicrobial 
stewardship
 • Operational benefits: e.g. through secondary uses of 
data surrounding drug usage/expenditure, reduction 
in waste, quicker discharge process, and time savings 
for staff
 • Managerial benefits: e.g. historical data for quality 
improvement by reviewing clinical management 
of patients and creating learning organisations, 
facilitating audits, and enhanced ability for workforce 
management.
However, none of these organisations had a closed-loop 
system (i.e. one that manages, dispenses and adminis-
ters),23 which may have prevented them from realising 
maximum benefits associated with barcode patient iden-
tification, integrated patient-specific details, medication 
administration, and automated dispensing. Such closed-loop 
approaches are more advanced, more complex and more ex-
pensive to implement, as they affect many different areas of 
organisational functioning. 
At an organisational level, participants discussed the 
necessity to move from these proxies towards measuring 
more direct financial impacts through more efficient captur-
ing and analysis of data. The best way for implementation 
teams within the NHS to achieve this was argued to be by 
‘doing simple things well’, that is, by devising tools that 
facilitate the recording and analysis of data without being 
too time consuming for users, technologically complex or 
expensive. A similar argument for simplicity was expressed 
in relation to measurements of quality, with participants 
arguing for a need to focus on a limited number of quality 
indicators when measuring system impacts. 
‘The most important thing I remember was: less is more…
define very carefully what you want to improve because 
too much information – nobody will read, nobody will 
understand.’ Participant 17, Industry
Engaging users (e.g. doctors, nurses and pharmacists), who 
were arguably instrumental in ensuring data availability and 
quality, was seen as a central component of an organisational 
move towards meaningful analysis of data. Incentives were 
seen to include individual access to data and associated per-
sonalised tailored analytic feedback, for example in relation to 
an individual’s clinical performance. This was also seen as a 
potential means to help bridge the gaps relating to maximis-
ing use and differences in perceived benefits between users, 
management, and data analysts. 
Learning optimisation-related lessons from other health-
care organisations and from internal ventures was viewed 
as an important component on the way towards meaningful 
analysis of data, in order to direct existing efforts, anticipate 
benefits and measure these more effectively. However, there 
was a perceived lack of sharing practice in the NHS, particu-
larly if these were innovative. 
Developing a national data strategy to allow 
analysis of generalised data
Participants highlighted the importance of differentiating 
between using data for specific and for generalised purposes. 
Whilst organisational improvements and analysis discussed 
above were seen as central to realising local organisational 
benefits, there was also a perceived need to begin approach-
ing the measurement of national returns through larger-scale 
data analytics and linkage across care settings. 
A generalised analytics infrastructure was seen as central 
to achieving this. Participants argued that this should include 
a national data strategy with specified data standards, allow-
ing integration of data across settings, and helping suppliers to 
develop interoperable systems and adequate analytics tools. 
‘I think the connecting thing in there is a data map or 
a data strategy… until we do that from the top down 
we’ll always end up with project based type data.’ 
Participant 15, Innovation Centre
As part of a national data strategy, participants also called 
for the development of a ‘gold standard’ of organisational 
processes against which individual organisational progress 
could be measured. As currently organisational processes 
vary significantly and are often not well documented, this 
would benefit organisations in helping to measure local ben-
efits and help to build a more integrated national analytics 
infrastructure. 
‘I think one of the things that I have personally struggled 
with is, before you can measure return on investment 
you have to find out what is the ideal way.’ Participant 17, 
Industry
Looking ahead: capturing and real-time 
analysis of data to predict care pathways
In the future, an exponential growth in data was expected with 
a range of clinical users and patients themselves collecting 
information through increasingly portable technologies. A part-
nership with commercial companies and academia to analyse 
these increasing amounts of data was, in light of the lack of 
resources and expertise within the NHS outlined above, viewed 
as a viable future option. Some such partnerships existed 
between the NHS and the pharmaceutical industry, but partici-
pants highlighted that there was a significant potential for this to 
work on larger scales and with other industries. 
A representative from the pharmaceutical industry 
described such a joint venture as follows:
‘…we’re providing resource in terms of analytics to 
 actually validate the [NHS] datasets…and that feeds 
our ability to price our medicines in the future according 
to indications. So that’s why we’re doing it…what they 
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[the NHS] are getting is reports that they want at the 
Trust level…so we can provide them with bespoke ana-
lytics using a resource that we’re paying for. That drives 
up the data quality and it fulfils our need in the future...’ 
Participant 13, Pharmaceutical Company
Overall, the NHS was seen to be far behind commercial 
industries in terms of data analytics capability. Contributing to 
this was the lack of leadership, the difficulty engaging users 
and the limited resources and expertise discussed above. In 
addition, participants stated that the NHS often neglected the 
content or presentation of data (where available), which was 
perceived to reduce the value of that information. Technologi-
cal limitations were not perceived to hamper efficient exploi-
tation of data in the NHS. 
As some promising future developments resulting from 
an increasing amount of data, participants referred to recent 
advances in machine learning and predictive data analyt-
ics that could be applied to prescribing. These were seen to 
potentially involve drawing on algorithms for predictive model-
ling, particularly in relation to minimising the risk of hospital 
admission and readmission in those with long-term conditions. 
‘As you start to accumulate a set of records about 
a patient and their health over some time, we have 
 algorithms that can predict what is your health going to 
look like in five years and what types of choices might 
you make as a patient that could change what your 
health looks like in five years.’ Participant 21, Prescribing 
Software Company
DISCUSSION
There was a general lack of clarity amongst participants as 
to how financial returns from ePrescribing systems could be 
realised and measured, although a range of qualitative ben-
efits from systems were reported in hospitals that had already 
implemented. Data analytics was viewed as an area with sig-
nificant future potential. Hampering progress in this area was 
the fact that the NHS lacked appropriate resources and exper-
tise to meaningfully analyse ePrescribing data, but also a lack 
of central guidance in relation to the collection, aggregation 
and analysis of localised and generalised datasets.
The range of sectors represented in this work is a clear 
strength, which was also reflected in the vibrant discussions 
and the enthusiastic feedback of participants. Participants 
were highly motivated to attend a discussion of what they 
perceived to be an important topic. Our results have real 
policy significance relating to current and future strategies. 
Nonetheless, there are also some important limitations, in-
cluding finding the right balance of the number of partici-
pants. We aimed at maximum sector representation, but 
this resulted in a large number of stakeholders being pres-
ent. Due to the large group, not everyone may have been 
able to voice all their concerns as they may not have had 
the chance to contribute. In addition, the facilitators were 
not trained qualitative researchers, but they did have cred-
ibility amongst participants as they are well-known figures 
in the area. Other limitations of this work include the rela-
tively small number of participants, which may limit gener-
alisability of findings; the lack of representation from some 
sectors and professions (e.g. junior doctors, nurses) and the 
limited time, which may have prevented some of the topics 
from being explored in sufficient depth. Nevertheless, we 
have provided important qualitative, experiential data in an 
emerging field.
A range of policy recommendations emerge from this work, 
which we have summarised in Box 4. Central to these is the 
development of a more coherent national data strategy taking 
into account the use and reuse of data held within systems to 
help organisations realise benefits and facilitate the collection of 
national datasets. ePrescribing systems lend themselves well to 
these deliberations, as they require digital transformations that 
transcend organisational and professional boundaries. The data 
collected through ePrescribing systems therefore have a range 
of potential individual, organisational and national applications.
Box 4 Policy recommendations for the U.K. emerging 
from this work
A more coherent national data strategy, facilitating the 
use and reuse of localised and generalised data
Identify meaningful proxies for measuring RoIs and 
applying these to a ‘gold standard’ that is nationally 
agreed and locally applied
Identifying the range of data that need to be the focus of 
short-, medium- and longer-term analyses for local and 
national efforts
Identify future technologies with the highest potential 
benefits and invest in future developments whilst 
harnessing the technologies that are already 
implemented
Deliberate potential risks relating to future uses of 
localised and generalised data and develop a strategy to 
mitigate these
As we have seen, participants advocated the develop-
ment of agreed organisational processes against which 
individual organisational progress could be measured. Some 
of this work has already begun through the efforts of analyt-
ics companies such as the Health Information and Manage-
ment Systems Society. This is a not-for-profit organisation 
that measures hospitals’ progress towards achieving a ‘gold 
standard’ of HIT implementation, commonly conceptualised 
as healthcare organisations drawing on electronic data to 
improve safety, quality and organisational efficiency.24 In 
relation to ePrescribing, this gold standard would consist of 
a closed-loop system that would allow effective secondary 
uses of data to improve performance, advanced refinement 
of decision support tools through integration with clinical 
notes, and increased automation resulting in less need for 
human involvement (e.g. in relation to dispensing). Howev-
er, although some local hospitals draw on this work, there is 
to date no central guidance on incorporating such achieve-
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ments in the U.K. This stays in stark contrast to U.S.  policy, 
where, due to the different health system and financial 
arrangements, achieving this level of integration is a central 
aim of governmental efforts.1 
It is also important that any future strategy is cognisant 
of the exponential growth of data and increasing number of 
 devices to collect these data. ePrescribing systems gener-
ate data collected by a range of professions (doctors, nurses, 
pharmacists and allied health professions) through a num-
ber of means, including handheld devices, desktops and 
computers on wheels. A data strategy will need to consider 
what range of data should be the focus of short-,  medium- 
and longer-term analyses, as organisations may get over-
whelmed by the sheer amount of possibilities available and 
are likely to have limited resources. ePrescribing analytics 
priorities may, for instance, involve important issues sur-
rounding antimicrobial stewardship, which is now high on 
local and national agendas and has the potential to affect a 
range of professional and organisational behaviours.25 Such 
a work will also have to involve considering the related issue of 
local and national data analysis resources. New career path-
ways (e.g. specialist training) will have to be developed to 
promote data analytics expertise within the NHS and a dis-
cussion surrounding the potential exploitation of collected 
data through third parties (such as pharmaceutical compa-
nies) is an area rife for discussion. 
Participants have alluded to the exciting opportunities 
presented through the ever-growing range of technolo-
gies. Whilst important to harvest new prospects (such as, 
for example, the role of artificial intelligence to diagnose 
disease, which has been shown to outperform humans in 
patient outcomes and cost),26 it is also important to con-
centrate on optimising existing technologies. This is par-
ticularly true in light of the findings that socio-economic 
 returns from complex health technologies are likely to take 
a long time to materialise.27 Any future strategy will have 
to take these long timelines into account and should aim to 
develop meaningful measurements of potential RoIs, draw-
ing on existing international expertise. ePrescribing systems 
are just at the beginning of the optimisation journey, which is 
likely to be an ongoing venture.28
Our participants outlined several categories of benefits, but 
these were proxies for financial benefits in discreet areas. 
Similar issues measuring direct financial impacts are faced 
by the international community, where financial returns may 
be discovered (possibly as a result of better data availability), 
but measured through proxies such as prescribing and medi-
cation guidance provided by the system, improved compli-
ance to guidelines, better legibility, time savings of healthcare 
professionals, and prevention of adverse drug events.29,30 
The work surrounding information infrastructures, which 
draws on other industries, can help us to understand the 
challenges surrounding potential future scenarios of ePrescrib-
ing systems in more detail. These may include the standardi-
sation of data formats, considerations surrounding access 
methods, implications for users when navigating additional 
interfaces that connect systems for aggregating data, align-
ing different long-term goals between stakeholders to achieve 
sustainability, devising security systems, and legal implica-
tions, and intellectual property considerations (e.g. surround-
ing locally developed analysis methods and systems). As has 
previously been argued, these aspects need to be taken into 
account when considering how data are exchanged on large 
scales, as they can hinder effective sharing and analysis.21 
For example, as our participants have argued, discussions 
surrounding anonymity do not feature in commercial discus-
sions surrounding ‘Big Data’, but anonymity and security 
represents a real ethical problem for healthcare systems. 
We therefore need to view healthcare systems (including 
ePrescribing) as potentially even more complex information 
infrastructures than those already in place in other sectors. 
Similarly, management of information infrastructures needs 
to take into account a wider range of considerations than in 
some other sectors. These may, for instance, relate to long-
term developments and formats of information. ePrescribing 
systems will generate data over long periods of time and are 
likely to be replaced with new technologies.31 As a result, 
they will generate data in different formats that will need to 
be integrated. 
CONCLUSIONS
This work is an important starting point relating to consid-
erations surrounding the realisation of financial returns from 
ePrescribing systems and data analytics. The range of stake-
holders and motivations represented has contributed towards 
developing a comprehensive perspective. 
Although explored in the context of a publicly funded health 
service, there are also some transferable lessons for priva-
tised systems, particularly surrounding the management of 
increasingly complex information infrastructures. Financial 
benefits can be accelerated if data are aggregated across 
settings and this remains an international challenge, particu-
larly in privatised health systems where incentives for larger-
scale aggregation are often limited for individual providers. 
The issue will become more pressing with time, as we collect 
increasing amounts of electronic data with a growing range of 
devices. The need to justify expenditures will remain as pres-
sures on health systems are likely to increase. 
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